C2C Wealth Management LLC Takes $37,000 Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)

C2C Wealth Management LLC acquired a new position in Puma Biotechnology, Inc. (NASDAQ:PBYI) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 12,000 shares of the biopharmaceutical company’s stock, valued at approximately $37,000.

A number of other institutional investors and hedge funds have also bought and sold shares of PBYI. Victory Capital Management Inc. increased its stake in Puma Biotechnology by 111.9% during the third quarter. Victory Capital Management Inc. now owns 35,097 shares of the biopharmaceutical company’s stock valued at $89,000 after acquiring an additional 18,532 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Puma Biotechnology during the third quarter valued at approximately $44,000. FMR LLC raised its stake in shares of Puma Biotechnology by 27.1% in the third quarter. FMR LLC now owns 118,265 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 25,183 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Puma Biotechnology by 2,002.5% in the third quarter. BNP Paribas Financial Markets now owns 67,702 shares of the biopharmaceutical company’s stock worth $173,000 after purchasing an additional 64,482 shares during the period. Finally, State Street Corp lifted its position in Puma Biotechnology by 17.0% in the third quarter. State Street Corp now owns 601,542 shares of the biopharmaceutical company’s stock worth $1,534,000 after purchasing an additional 87,504 shares during the period. Institutional investors own 61.29% of the company’s stock.

Insider Activity

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 33,841 shares of Puma Biotechnology stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $106,599.15. Following the completion of the transaction, the chief executive officer now owns 7,029,674 shares in the company, valued at approximately $22,143,473.10. The trade was a 0.48 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $29,726.55. Following the completion of the transaction, the insider now directly owns 108,951 shares in the company, valued at approximately $343,195.65. This represents a 7.97 % decrease in their position. The disclosure for this sale can be found here. 23.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. StockNews.com cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 8th. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Puma Biotechnology in a research note on Friday, February 28th.

Puma Biotechnology Price Performance

Shares of PBYI stock opened at $3.14 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40. The stock’s fifty day simple moving average is $3.10 and its 200 day simple moving average is $2.97. Puma Biotechnology, Inc. has a one year low of $2.23 and a one year high of $6.06. The firm has a market cap of $155.78 million, a price-to-earnings ratio of 6.54 and a beta of 1.33.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.29. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The business had revenue of $59.10 million for the quarter, compared to analyst estimates of $52.50 million. On average, analysts expect that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.